Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Azilsartan in Pediatric Hypertension
NCT02451150Phase 3Completed
- Sponsor
- Takeda
- Start
- Aug 2015
- Primary completion
- Sep 2015
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, open-label trial of azilsartan in hypertension (HTN), sponsored by Takeda. Primary endpoints: Area Under the Plasma Concentration-Time Curve From Time 0 to Time 24 Hours of Azilsartan, Maximum Observed Plasma Concentration of Azilsartan at 24 hours and 21 more. Started Aug 2015; status: completed.
02
Drugs
azilsartan
03
Conditions
hypertension (HTN)
Beyond the preview
Go deeper on NCT02451150.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02451150.